StreetAlpha.app
Home › Stocks › ANAB

Anaptysbio, Inc (ANAB)

Healthcare
$46.63
▼ −1.62%
LAST CLOSE · NOV 20

AnaptysBio collects royalties from the cancer treatment Jemperli and the psoriasis treatment Quimilza, which partners GSK and Vanda sell. It last closed at $46.63 on Nov 20, down 1.62% on the day. The next earnings report for ANAB is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, ANAB reported EPS of $0.11 on revenue of $30.3M, with revenue down 60.3% from a year ago. Over its last 8 reports the stock moved an average of 6.3% the session after earnings. Over the last 12 months ANAB insiders bought $17.2M of stock on the open market and sold $9.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is ANAB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANAB.

Key Stats

Last 12 months
Results
Revenue
$191.6M
+13.0% vs a year ago
Net income
$184.5M
96.3% margin
EPS (diluted)
$5.33
Operating margin
155.6%
$298.1M operating income
Valuation
Market cap
$1.4B
29.7M shares
P/E
8.7
Price over 12 month EPS
Price to sales
7.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$135.4M
At Sep 30
Shareholder equity
$20.8M
Buybacks
$3.4M
Last 12 months
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2021: $63.2M$63.2MFY2021FY2022: $10.3M$10.3MFY2022FY2023: $17.2M$17.2MFY2023FY2024: $91.3M$91.3MFY2024FY2025: $234.6M$234.6MFY2025

From ANAB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · After the close
Reported EPS
$0.11
Quarter ended Sep 2026
Year ago EPS
$0.52
−78.8% on a GAAP basis
Revenue
$30.3M
−60.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.46Dec '24Mar 2025: -$1.28Mar '25Jun 2025: -$1.34Jun '25Sep 2025: $0.52Sep '25Dec 2025: $1.72Dec '25Mar 2026: -$1.84Mar '26Jun 2026: $5.34Jun '26Sep 2026: $0.11Sep '26Latest $0.11
Revenue by quarter
Dec 2024: $43.1MDec '24Mar 2025: $27.8MMar '25Jun 2025: $22.3MJun '25Sep 2025: $76.3MSep '25Dec 2025: $108.2MDec '25Mar 2026: $25.6MMar '26Jun 2026: $27.5MJun '26Sep 2026: $30.3MSep '26Latest $30.3M
How ANAB moved after its last 8 reports
Average move the session after a report ±6.3%
Nov 12, 2026After the close−3.2%
May 12, 2026After the close−4.4%
Mar 3, 2026After the close+14.6%
Jan 9, 2026After the close+9.8%
Nov 4, 2025After the close+3.6%
Aug 6, 2025After the close−9.6%
May 5, 2025After the close−2.9%
Feb 27, 2025After the close+2.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ANABStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ANAB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ANAB

Technical Analysis

ANAB · as of the Nov 20 close · updated each morning
Downtrend

The stock is 2% below its 20 day and 5% below its 50 day average. It is 21% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot S1 at $45.88, and the nearest resistance the Pivot at $46.80.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityLow, 4.4%/day
Key levels
$73.3052 week high+57.2%
$56.44200 day average+21.0%
$53.12100 day average+13.9%
$49.00Swing high (Nov 4)+5.1%
$48.8850 day average+4.8%
$47.5820 day average+2.0%
$47.54Pivot R1+2.0%
$46.80Pivot+0.4%
$46.63Last close
$45.88Pivot S1−1.6%
$45.01Swing low (Nov 6)−3.5%
$33.1052 week low−29.0%
Indicators
RSI (14)45.50Middle of its rangeNeutral
MACD-0.63Above its signal lineBullish
Stochastic49.1Middle of its rangeNeutral
ADX (14)21.2Weak trend
Williams %R-60.8Oversold below −80, overbought above −20Neutral
CCI (20)-49.0Oversold below −100, overbought above 100Neutral
Rate of change+0.4%Change over 10 sessionsBullish
ATR (14)$2.07Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANAB

What happened before

See how ANAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ANAB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ANAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ANABHow many large options trades hit ANAB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ANAB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲138 buying vs 97 selling
  • ▲Held by funds +2.3 pts
  • ▲Funds holding +15
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding229214+7.0%
In funds' top 1067−14.3%
Held by funds103.8%101.4%+2.3 pts
New / increased50 / 8844 / 74+16.9%
Reduced / sold out62 / 3565 / 37−4.9%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANAB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ANAB Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$17.2M1 buy · 1 insider
Sold$9.8M23 sales · 8 insiders
37% of the selling was under pre-arranged trading plans.
2025-12 sold $3.0M2026-01 sold $3.7M2026-02 sold $540K2026-03 sold $2.2M2026-10 sold $249K2026-11 bought $17.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18EcoR1 Capital, LLCDirectorBuy374,580$45.98$17.2M
Oct 1Hollings RentonDirectorSale plan5,000$49.87$249K
Mar 30John P. SchmidDirectorSale20,645$56.11$1.2M
Mar 27Daniel FagaPresident, CEOSale17,679$61.61$1.1M
Feb 11Eric J LoumeauChief Legal OfficerSale plan10,000$54.00$540K
Jan 15Magda MarquetDirectorSale11,000$48.23$531K
Every insider buy and sale for ANAB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANAB insider trades →

From SEC Form 4 filings by ANAB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANAB is in one of them and how their past ANAB trades turned out.

ANAB in the AI portfolios
Loading…

ANAB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANAB in an article yet. Here's the latest on the wider market.

ANAB in the news

About Anaptysbio

AnaptysBio is a pharmaceutical company based in San Diego, California, whose business centers on collecting royalties from medicines it has licensed to others. It receives royalties on Jemperli, a cancer treatment developed and sold by GSK, and on Quimilza, a treatment for generalized pustular psoriasis that Vanda Pharmaceuticals is developing and commercializing. The company does not develop or sell these products itself, so its payments depend on the sales of its partners.

Headquarters
San Diego, CA